Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Metuchen takes US, Canadian license to Vivus' Stendra

Executive Summary

Metuchen Pharmaceuticals LLC licensed exclusive commercialization rights in the US, Canada, South America, and India to Vivus Inc.'s Stendra (avanafil)--an oral phosphodiesterase-5 inhibitor with a rapid onset of action for erectile dysfunction--which was approved in the US in 2012 and in Europe (where it's known as Spedra) in 2013.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies